Prot #B1931022: An Open-label, Randomized Phase 3 Study of Inotuzumab Ozogamicin Compared to a Defined Investigator's Choice in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)

Project: Research project

Project Details

StatusFinished
Effective start/end date4/24/134/24/19

Funding

  • ICON Clinical Research, LLC (Prot #B1931022)
  • Pfizer Inc. (Prot #B1931022)